GEHC

$69.65-0.73 (-1.04%)

Market ClosedAs of Mar 20, 8:00 PM UTC

GE HealthCare Technologies Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$69.65
Potential Upside
45.8%
Whystock Fair Value$101.54
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internati...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.31
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
21.58%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.13

Recent News

Zacks
Mar 20, 2026

GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities

GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 19, 2026

Stryker Investors Weigh Cyberattack Recovery As CEO Joins GE HealthCare Board

Stryker CEO Kevin Lobo has been appointed to the Board of Directors of GE HealthCare. The appointment links leadership at two large medical technology companies with global reach. Stryker, traded as NYSE:SYK, enters this leadership development with its shares at $345.81. Over the past 3 years the stock shows a total return of 30.7%, and over 5 years a total return of 55.7%, which gives investors some historical context for how the company has rewarded long term holders. For investors...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 19, 2026

GEHC & Springbok Collaborate on MRI Muscle Analysis for Sports

GE HealthCare teams with Springbok to pair MRI tech with AI muscle analytics, aiming to redefine how muscle health is measured and visualized.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 19, 2026

Hologic's Women's Health Index Flags Alarming Gaps in STI Screening

HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 18, 2026

Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?

Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.

BEARISH
Negative press. News cycle fixated on risk factors or misses.